CN115768420A - 用于治疗肺部非结核分枝杆菌感染的三联抗生素固定剂量组合产品、给药方案、方法和试剂盒 - Google Patents

用于治疗肺部非结核分枝杆菌感染的三联抗生素固定剂量组合产品、给药方案、方法和试剂盒 Download PDF

Info

Publication number
CN115768420A
CN115768420A CN202180044988.XA CN202180044988A CN115768420A CN 115768420 A CN115768420 A CN 115768420A CN 202180044988 A CN202180044988 A CN 202180044988A CN 115768420 A CN115768420 A CN 115768420A
Authority
CN
China
Prior art keywords
dose
fixed
clarithromycin
clofazimine
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180044988.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·法西
吉利德·拉戴
P·安德森
E·奥夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of CN115768420A publication Critical patent/CN115768420A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180044988.XA 2020-06-30 2021-06-30 用于治疗肺部非结核分枝杆菌感染的三联抗生素固定剂量组合产品、给药方案、方法和试剂盒 Pending CN115768420A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046335P 2020-06-30 2020-06-30
US202063046322P 2020-06-30 2020-06-30
US63/046,335 2020-06-30
US63/046,322 2020-06-30
PCT/IB2021/000451 WO2022003421A2 (en) 2020-06-30 2021-06-30 Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections

Publications (1)

Publication Number Publication Date
CN115768420A true CN115768420A (zh) 2023-03-07

Family

ID=79032054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180044988.XA Pending CN115768420A (zh) 2020-06-30 2021-06-30 用于治疗肺部非结核分枝杆菌感染的三联抗生素固定剂量组合产品、给药方案、方法和试剂盒

Country Status (11)

Country Link
US (1) US11590154B2 (https=)
EP (1) EP4171546A4 (https=)
JP (1) JP2023533472A (https=)
KR (1) KR20230028502A (https=)
CN (1) CN115768420A (https=)
AU (1) AU2021298936A1 (https=)
BR (1) BR112022026615A2 (https=)
CA (1) CA3187031A1 (https=)
IL (1) IL299287A (https=)
MX (1) MX2023000165A (https=)
WO (1) WO2022003421A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059136A1 (en) * 2008-02-08 2011-03-10 Thomas Julius Borody Methods and Compositions for Treating Inflammatory Bowel Disease
CN103813797A (zh) * 2011-09-20 2014-05-21 红山生物医药有限公司 一种用于治疗自身免疫性疾病的组合物和方法
US20180273573A1 (en) * 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012304A1 (es) 1997-04-01 2000-10-18 Borody Thomas J Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
WO2017194734A1 (en) 2016-05-13 2017-11-16 Technische Universität München Means and methods for treating mycobacterial diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059136A1 (en) * 2008-02-08 2011-03-10 Thomas Julius Borody Methods and Compositions for Treating Inflammatory Bowel Disease
CN103813797A (zh) * 2011-09-20 2014-05-21 红山生物医药有限公司 一种用于治疗自身免疫性疾病的组合物和方法
US20180273573A1 (en) * 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAEFNER, M等: "Clarithromycin, rifabutin and clofazimine for treatment of disseminated Mycobacterium avium complex disease in AIDS patients", 《CLINICAL DRUG INVESTIGATION》, vol. 17, no. 3, 30 March 1999 (1999-03-30), pages 171 - 178, XP009145079 *
STGEORGIEV, V: "TREATMENT AND DEVELOPMENTAL THERAPEUTICS OF MYCOBACTERIUM-AVIUM COMPLEX (MAC) INFECTIONS", 《INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS》, vol. 4, no. 4, 30 November 1994 (1994-11-30), pages 247 - 270, XP023923355, DOI: 10.1016/0924-8579(94)90025-6 *
YAJKO, DM等: "In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》, vol. 40, no. 3, 31 March 1996 (1996-03-31), pages 743 - 749 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Also Published As

Publication number Publication date
US11590154B2 (en) 2023-02-28
US20210401865A1 (en) 2021-12-30
EP4171546A4 (en) 2024-03-13
CA3187031A1 (en) 2022-01-06
IL299287A (en) 2023-02-01
EP4171546A2 (en) 2023-05-03
BR112022026615A2 (pt) 2023-01-24
MX2023000165A (es) 2023-02-22
WO2022003421A3 (en) 2022-03-17
JP2023533472A (ja) 2023-08-03
WO2022003421A2 (en) 2022-01-06
KR20230028502A (ko) 2023-02-28
AU2021298936A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Xu et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis
Nuermberger et al. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
Nuermberger et al. Current development and future prospects in chemotherapy of tuberculosis
Lue et al. Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks
Rosenthal et al. Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis
Tato et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates
Bradford et al. Multiple drug–resistant tuberculosis
Zheng et al. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models
Laohapojanart et al. Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial
EP3908269A1 (en) Combination in the treatment of nontuberculous mycobacterial diseases
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
Dutta et al. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice
CN117045657A (zh) 一种药物组合及其应用
Sano et al. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium
CN115768420A (zh) 用于治疗肺部非结核分枝杆菌感染的三联抗生素固定剂量组合产品、给药方案、方法和试剂盒
US20260007650A1 (en) Methods for the treatment and prevention of lung infections caused by fungus by administration of tafenoquine
Bishai et al. Short-course chemoprophylaxis for tuberculosis
CN119564683B (zh) 一种抗分枝杆菌感染的联合增效药物组合物
CN116406270A (zh) 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
Kaur et al. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria
CN112089713A (zh) 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物
Zheng et al. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and
Horiguchi et al. Antibacterial activity and clinical efficacy of sparfloxacin in Mycobacterium avium-intracellulare complex infection
Cole et al. Highlights from the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
WO2023107149A1 (en) Non-tuberculosis mycobacteria infection treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination